The Association of Physicians of India (API) recognises Omeprazole as a Safer PPI in APD management1

1. Safety in Geriatric and Pediatric Populations

• As per the US FDA, Omeprazole has proven safety in geriatric and pediatric populations2

2. Hepatic Safety

• As per the review and analysis of 69 articles by an expert panel published in the British Journal of Clinical Pharmacology (August 2018)3

• Omeprazole – Safer in CTP A and CTP B patients than pantoprazole

• Omeprazole – PPI with "no additional risks known" for cirrhotic patients

3. Renal Safety

• According to a clinical trial conducted in 5994 patients, International Diabetes Federation (2019)4

• No associated increase in the risk of CKD with Omeprazole after 1 year of use

• Omeprazole – PPI of choice in diabetic patients over pantoprazole

4. Pregnancy safety

• According to World Gastroenterology Global Guidelines (July 2017)5

• Omeprazole (only Category B PPI) has the largest human experience for use in pregnancy

5. COVID compliance

• WHO recommends Omeprazole as one of the useful oral medicines for prevention and relief of physical suffering related to Covid-196

• Omeprazole is the only PPI featuring in WHO Covid 19 Clinical management guidelines

6. Omeprazole is not only safe but also affordable

• Omeprazole is 66% economical than leading pantoprazole brands*

1. S. Arhulraj, Mangesh Tiwaskar, T. S. Chandrasekar Acid-Peptic Disorder Management:- Omeprazole, A Safer Option: Thieme Publishing Group, Delhi.2020 p.7-36.

2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf. Accessed on 27.10.2021.

3. Weersink RA et. al., Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018 Aug;84(8):1806–20.

4. Yang H et. al., Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019 Jan;147:67–75.

5. Hunt et. al., World Gastroenterology Organisation Global Guidelines, Journal of Clinical Gastroenterology: July 2017 - Volume 51 - Issue 6 - p 467-78.

6. https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf.

* Average Costing for top selling brands for each molecule